Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-07-04

AUTHORS

Aurélie Bourmaud, Emilie Henin, Fabien Tinquaut, Véronique Regnier, Chloé Hamant, Olivier Colomban, Benoit You, Florence Ranchon, Jérôme Guitton, Pascal Girard, Gilles Freyer, Michel Tod, Catherine Rioufol, Véronique Trillet-Lenoir, Franck Chauvin

ABSTRACT

BackgroundNumerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients’ adherence profiles using a qualitative–quantitative method.MethodsA capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients’ beliefs was reported using a questionnaire. Later, Information on patients’ relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.Results38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6 months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative’s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p = 0.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.ConclusionsThese encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects. More... »

PAGES

291

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8

DOI

http://dx.doi.org/10.1186/s13104-015-1231-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1034594045

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26142140


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medication Adherence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Qualitative Research", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bourmaud", 
        "givenName": "Aur\u00e9lie", 
        "id": "sg:person.0712122560.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712122560.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Henin", 
        "givenName": "Emilie", 
        "id": "sg:person.01033714476.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033714476.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tinquaut", 
        "givenName": "Fabien", 
        "id": "sg:person.0644007360.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644007360.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Regnier", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.0653777465.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653777465.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
          "id": "http://www.grid.ac/institutes/grid.7429.8", 
          "name": [
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hamant", 
        "givenName": "Chlo\u00e9", 
        "id": "sg:person.0722112665.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722112665.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colomban", 
        "givenName": "Olivier", 
        "id": "sg:person.01125155725.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125155725.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "You", 
        "givenName": "Benoit", 
        "id": "sg:person.0653052265.95", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653052265.95"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ranchon", 
        "givenName": "Florence", 
        "id": "sg:person.01173517743.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173517743.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.413852.9", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Guitton", 
        "givenName": "J\u00e9r\u00f4me", 
        "id": "sg:person.0651232245.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651232245.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Girard", 
        "givenName": "Pascal", 
        "id": "sg:person.012661201622.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012661201622.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Freyer", 
        "givenName": "Gilles", 
        "id": "sg:person.0636233052.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636233052.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.7849.2", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tod", 
        "givenName": "Michel", 
        "id": "sg:person.0763711421.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763711421.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rioufol", 
        "givenName": "Catherine", 
        "id": "sg:person.01301001714.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301001714.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Trillet-Lenoir", 
        "givenName": "V\u00e9ronique", 
        "id": "sg:person.01352404762.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352404762.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Jean Monnet University, Saint-Etienne, France", 
          "id": "http://www.grid.ac/institutes/grid.6279.a", 
          "name": [
            "EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France", 
            "Public Health Department, Hyg\u00e9e Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France", 
            "Jean Monnet University, Saint-Etienne, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chauvin", 
        "givenName": "Franck", 
        "id": "sg:person.01035013747.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035013747.60"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s002280050077", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027739420", 
          "https://doi.org/10.1007/s002280050077"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-010-0927-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041708807", 
          "https://doi.org/10.1007/s00520-010-0927-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-009-0366-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032462874", 
          "https://doi.org/10.1007/s10549-009-0366-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13187-013-0511-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036647518", 
          "https://doi.org/10.1007/s13187-013-0511-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-07-04", 
    "datePublishedReg": "2015-07-04", 
    "description": "BackgroundNumerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients\u2019 adherence profiles using a qualitative\u2013quantitative method.MethodsA capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients\u2019 beliefs was reported using a questionnaire. Later, Information on patients\u2019 relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.Results38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6\u00a0months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative\u2019s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p\u00a0=\u00a00.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.ConclusionsThese encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13104-015-1231-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1039457", 
        "issn": [
          "1756-0500"
        ], 
        "name": "BMC Research Notes", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "keywords": [
      "side effects", 
      "electronic Medication Event Monitoring System", 
      "Medication Event Monitoring System", 
      "anticancer chemotherapy", 
      "treatment side effects", 
      "Event Monitoring System", 
      "advanced breast", 
      "capecitabine treatment", 
      "adverse events", 
      "colorectal cancer", 
      "treatment adherence", 
      "adequate adherence", 
      "patients' beliefs", 
      "low adherence", 
      "patient profiles", 
      "patients", 
      "patient clusters", 
      "adherence profiles", 
      "chemotherapy", 
      "adherence", 
      "Further studies", 
      "treatment", 
      "questionnaire", 
      "risk", 
      "active life", 
      "multiple classification analysis", 
      "profile B", 
      "educational programs", 
      "capecitabine", 
      "cancer", 
      "breast", 
      "months", 
      "efficacy", 
      "study", 
      "interviews", 
      "effect", 
      "primary results", 
      "profile", 
      "inclusion", 
      "octo", 
      "life", 
      "classification analysis", 
      "events", 
      "analysis", 
      "quantitative-qualitative method", 
      "objective", 
      "beliefs", 
      "results", 
      "program", 
      "information", 
      "qualitative-quantitative method", 
      "method", 
      "tendency", 
      "monitoring system", 
      "relation", 
      "system", 
      "clusters", 
      "sociologists", 
      "MEMS"
    ], 
    "name": "Adherence to oral anticancer chemotherapy: What influences patients\u2019 over or non-adherence? Analysis of the OCTO study through quantitative\u2013qualitative methods", 
    "pagination": "291", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1034594045"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13104-015-1231-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26142140"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13104-015-1231-8", 
      "https://app.dimensions.ai/details/publication/pub.1034594045"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_646.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13104-015-1231-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13104-015-1231-8'


 

This table displays all metadata directly associated to this object as RDF triples.

304 TRIPLES      21 PREDICATES      101 URIs      88 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13104-015-1231-8 schema:about N08f56588bca6457292393826ad5613e3
2 N0a1829ae9d9e4256b4cab76289198042
3 N0bd8e5d1eb3e468b9ec7380acb520dc0
4 N3bbbcca2d15842d89a9ad2f2af036447
5 N765347e3ccc24ad6b29f771775f56f34
6 N7fdd833a4c734144a7488e12951d69d0
7 N83499b34d9f649338324714982046ad1
8 Nab750340bdb8439eb4787c60e70ffd81
9 Nb60fe2b9df43483eaf76230eca014513
10 Nb779fb883602430686954010b7135855
11 Nbd1472592238436c8497534eeec8c004
12 Nd72d1b52971047998b91fb672dc5b94d
13 anzsrc-for:11
14 anzsrc-for:1112
15 anzsrc-for:1117
16 schema:author Nd1eafb710b744abd992581295eaca1ec
17 schema:citation sg:pub.10.1007/s002280050077
18 sg:pub.10.1007/s00520-010-0927-5
19 sg:pub.10.1007/s10549-009-0366-5
20 sg:pub.10.1007/s13187-013-0511-z
21 schema:datePublished 2015-07-04
22 schema:datePublishedReg 2015-07-04
23 schema:description BackgroundNumerous oral anticancer chemotherapies are available. Non-adherence or over-adherence to these chemotherapies can lead to lowered efficacy and increased risk of adverse events. The objective of this study was to identify patients’ adherence profiles using a qualitative–quantitative method.MethodsA capecitabine treatment was initiated for 38 patients with advanced breast or colorectal cancer. At inclusion, information on patients’ beliefs was reported using a questionnaire. Later, Information on patients’ relation to treatment was obtained from a sub-group during an interview with a sociologist. Questionnaires were analyzed using Multiple Classification Analysis to cluster patients. Treatment adherence was evaluated by an electronic medication event monitoring systems (MEMS caps) and then correlated with patient clusters. Interviews were analyzed to complete and explain results.Results38 patients were enrolled between 2008 and 2011 and completed the questionnaire. Twenty had adherence measured with MEMS caps all along treatment. Between 4 and 6 months after inclusion, 16 patients were interviewed. Patient profile B (retired, with a regular life, surrounded by a relative’s attention to drug adherence, with a low educational level) was statistically associated with adequate adherence (p = 0.049). A tendency for lower adherence was observed among more highly educated patients with an irregular, active life (NS). All patients taking capecitabine demonstrated a risk of over-adherence, potentiating side effects.ConclusionsThese encouraging primary results suggest that further studies should be undertaken and that educational programs tailored to patient profiles should be evaluated to enhance adherence for those who need it and to empower all patients to manage treatment side effects.
24 schema:genre article
25 schema:isAccessibleForFree true
26 schema:isPartOf N929035db571a469c8e6e0a4d25c51534
27 Na66dc3a743b34c3d9bf237dff8d8f918
28 sg:journal.1039457
29 schema:keywords Event Monitoring System
30 Further studies
31 MEMS
32 Medication Event Monitoring System
33 active life
34 adequate adherence
35 adherence
36 adherence profiles
37 advanced breast
38 adverse events
39 analysis
40 anticancer chemotherapy
41 beliefs
42 breast
43 cancer
44 capecitabine
45 capecitabine treatment
46 chemotherapy
47 classification analysis
48 clusters
49 colorectal cancer
50 educational programs
51 effect
52 efficacy
53 electronic Medication Event Monitoring System
54 events
55 inclusion
56 information
57 interviews
58 life
59 low adherence
60 method
61 monitoring system
62 months
63 multiple classification analysis
64 objective
65 octo
66 patient clusters
67 patient profiles
68 patients
69 patients' beliefs
70 primary results
71 profile
72 profile B
73 program
74 qualitative-quantitative method
75 quantitative-qualitative method
76 questionnaire
77 relation
78 results
79 risk
80 side effects
81 sociologists
82 study
83 system
84 tendency
85 treatment
86 treatment adherence
87 treatment side effects
88 schema:name Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods
89 schema:pagination 291
90 schema:productId N1ef0bb89ba3c4c1a94fa550a666b7f0a
91 N5077cda7e655461da5146379ae5f873d
92 Nad2b90de26b04811a42408e553d38a5f
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034594045
94 https://doi.org/10.1186/s13104-015-1231-8
95 schema:sdDatePublished 2022-12-01T06:32
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher N1b1679bd7b9c4fbca229b9fd9f3ea7c2
98 schema:url https://doi.org/10.1186/s13104-015-1231-8
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N004338b52d234c77968815bdcc062b50 rdf:first sg:person.0644007360.97
103 rdf:rest Na60c69754b214bffb6afe36038adf021
104 N06fac712f423485a8339e7cc70f55bef rdf:first sg:person.01352404762.56
105 rdf:rest N22415f8f73ab4b97974923aa2a9ec499
106 N08f56588bca6457292393826ad5613e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Qualitative Research
108 rdf:type schema:DefinedTerm
109 N09c5a42bcc4141838bf4b5eea0366715 rdf:first sg:person.01301001714.70
110 rdf:rest N06fac712f423485a8339e7cc70f55bef
111 N09ce127cd68e494e88c834237b3134a5 rdf:first sg:person.01173517743.97
112 rdf:rest N5216f5b3a6e64480bc82194f8c52ee76
113 N0a1829ae9d9e4256b4cab76289198042 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Antimetabolites, Antineoplastic
115 rdf:type schema:DefinedTerm
116 N0bd8e5d1eb3e468b9ec7380acb520dc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Middle Aged
118 rdf:type schema:DefinedTerm
119 N1b1679bd7b9c4fbca229b9fd9f3ea7c2 schema:name Springer Nature - SN SciGraph project
120 rdf:type schema:Organization
121 N1ef0bb89ba3c4c1a94fa550a666b7f0a schema:name doi
122 schema:value 10.1186/s13104-015-1231-8
123 rdf:type schema:PropertyValue
124 N22415f8f73ab4b97974923aa2a9ec499 rdf:first sg:person.01035013747.60
125 rdf:rest rdf:nil
126 N3bbbcca2d15842d89a9ad2f2af036447 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Capecitabine
128 rdf:type schema:DefinedTerm
129 N5077cda7e655461da5146379ae5f873d schema:name dimensions_id
130 schema:value pub.1034594045
131 rdf:type schema:PropertyValue
132 N5216f5b3a6e64480bc82194f8c52ee76 rdf:first sg:person.0651232245.54
133 rdf:rest N526f51ce4b6e47faa0276120f051a66f
134 N526f51ce4b6e47faa0276120f051a66f rdf:first sg:person.012661201622.56
135 rdf:rest Ne8e122802aee43098780b9f4d59197d8
136 N765347e3ccc24ad6b29f771775f56f34 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Aged
138 rdf:type schema:DefinedTerm
139 N7fdd833a4c734144a7488e12951d69d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Breast Neoplasms
141 rdf:type schema:DefinedTerm
142 N83499b34d9f649338324714982046ad1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Medication Adherence
144 rdf:type schema:DefinedTerm
145 N88f55e5c68794430966768c293b2fe9b rdf:first sg:person.01033714476.41
146 rdf:rest N004338b52d234c77968815bdcc062b50
147 N8a196a8c45544084b9b69e39a6e27ddc rdf:first sg:person.01125155725.09
148 rdf:rest Nda55e79792f84105b84ec496de129191
149 N929035db571a469c8e6e0a4d25c51534 schema:volumeNumber 8
150 rdf:type schema:PublicationVolume
151 Na60c69754b214bffb6afe36038adf021 rdf:first sg:person.0653777465.70
152 rdf:rest Nc228b70e6cba453491832dce9cdccabf
153 Na66dc3a743b34c3d9bf237dff8d8f918 schema:issueNumber 1
154 rdf:type schema:PublicationIssue
155 Nab750340bdb8439eb4787c60e70ffd81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Colorectal Neoplasms
157 rdf:type schema:DefinedTerm
158 Nad2b90de26b04811a42408e553d38a5f schema:name pubmed_id
159 schema:value 26142140
160 rdf:type schema:PropertyValue
161 Nb60fe2b9df43483eaf76230eca014513 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Male
163 rdf:type schema:DefinedTerm
164 Nb779fb883602430686954010b7135855 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Follow-Up Studies
166 rdf:type schema:DefinedTerm
167 Nbb9b0b9b4a3048ada404606f254c57e3 rdf:first sg:person.0763711421.46
168 rdf:rest N09c5a42bcc4141838bf4b5eea0366715
169 Nbd1472592238436c8497534eeec8c004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Female
171 rdf:type schema:DefinedTerm
172 Nc228b70e6cba453491832dce9cdccabf rdf:first sg:person.0722112665.51
173 rdf:rest N8a196a8c45544084b9b69e39a6e27ddc
174 Nd1eafb710b744abd992581295eaca1ec rdf:first sg:person.0712122560.89
175 rdf:rest N88f55e5c68794430966768c293b2fe9b
176 Nd72d1b52971047998b91fb672dc5b94d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Humans
178 rdf:type schema:DefinedTerm
179 Nda55e79792f84105b84ec496de129191 rdf:first sg:person.0653052265.95
180 rdf:rest N09ce127cd68e494e88c834237b3134a5
181 Ne8e122802aee43098780b9f4d59197d8 rdf:first sg:person.0636233052.33
182 rdf:rest Nbb9b0b9b4a3048ada404606f254c57e3
183 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
184 schema:name Medical and Health Sciences
185 rdf:type schema:DefinedTerm
186 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
187 schema:name Oncology and Carcinogenesis
188 rdf:type schema:DefinedTerm
189 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
190 schema:name Public Health and Health Services
191 rdf:type schema:DefinedTerm
192 sg:journal.1039457 schema:issn 1756-0500
193 schema:name BMC Research Notes
194 schema:publisher Springer Nature
195 rdf:type schema:Periodical
196 sg:person.01033714476.41 schema:affiliation grid-institutes:grid.7849.2
197 schema:familyName Henin
198 schema:givenName Emilie
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033714476.41
200 rdf:type schema:Person
201 sg:person.01035013747.60 schema:affiliation grid-institutes:grid.6279.a
202 schema:familyName Chauvin
203 schema:givenName Franck
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035013747.60
205 rdf:type schema:Person
206 sg:person.01125155725.09 schema:affiliation grid-institutes:grid.7849.2
207 schema:familyName Colomban
208 schema:givenName Olivier
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125155725.09
210 rdf:type schema:Person
211 sg:person.01173517743.97 schema:affiliation grid-institutes:None
212 schema:familyName Ranchon
213 schema:givenName Florence
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173517743.97
215 rdf:type schema:Person
216 sg:person.012661201622.56 schema:affiliation grid-institutes:grid.7849.2
217 schema:familyName Girard
218 schema:givenName Pascal
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012661201622.56
220 rdf:type schema:Person
221 sg:person.01301001714.70 schema:affiliation grid-institutes:None
222 schema:familyName Rioufol
223 schema:givenName Catherine
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01301001714.70
225 rdf:type schema:Person
226 sg:person.01352404762.56 schema:affiliation grid-institutes:None
227 schema:familyName Trillet-Lenoir
228 schema:givenName Véronique
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352404762.56
230 rdf:type schema:Person
231 sg:person.0636233052.33 schema:affiliation grid-institutes:None
232 schema:familyName Freyer
233 schema:givenName Gilles
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636233052.33
235 rdf:type schema:Person
236 sg:person.0644007360.97 schema:affiliation grid-institutes:grid.7429.8
237 schema:familyName Tinquaut
238 schema:givenName Fabien
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644007360.97
240 rdf:type schema:Person
241 sg:person.0651232245.54 schema:affiliation grid-institutes:grid.413852.9
242 schema:familyName Guitton
243 schema:givenName Jérôme
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651232245.54
245 rdf:type schema:Person
246 sg:person.0653052265.95 schema:affiliation grid-institutes:None
247 schema:familyName You
248 schema:givenName Benoit
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653052265.95
250 rdf:type schema:Person
251 sg:person.0653777465.70 schema:affiliation grid-institutes:grid.7429.8
252 schema:familyName Regnier
253 schema:givenName Véronique
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653777465.70
255 rdf:type schema:Person
256 sg:person.0712122560.89 schema:affiliation grid-institutes:grid.7429.8
257 schema:familyName Bourmaud
258 schema:givenName Aurélie
259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712122560.89
260 rdf:type schema:Person
261 sg:person.0722112665.51 schema:affiliation grid-institutes:grid.7429.8
262 schema:familyName Hamant
263 schema:givenName Chloé
264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722112665.51
265 rdf:type schema:Person
266 sg:person.0763711421.46 schema:affiliation grid-institutes:grid.7849.2
267 schema:familyName Tod
268 schema:givenName Michel
269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0763711421.46
270 rdf:type schema:Person
271 sg:pub.10.1007/s002280050077 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027739420
272 https://doi.org/10.1007/s002280050077
273 rdf:type schema:CreativeWork
274 sg:pub.10.1007/s00520-010-0927-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041708807
275 https://doi.org/10.1007/s00520-010-0927-5
276 rdf:type schema:CreativeWork
277 sg:pub.10.1007/s10549-009-0366-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032462874
278 https://doi.org/10.1007/s10549-009-0366-5
279 rdf:type schema:CreativeWork
280 sg:pub.10.1007/s13187-013-0511-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1036647518
281 https://doi.org/10.1007/s13187-013-0511-z
282 rdf:type schema:CreativeWork
283 grid-institutes:None schema:alternateName Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France
284 Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France
285 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
286 Medical Oncology Department, Teaching Hospital, Lyon-Sud University, Lyon, France
287 Oncologic Pharmaceutical Department, Lyon-Sud University Teaching Hospital, Lyon, France
288 rdf:type schema:Organization
289 grid-institutes:grid.413852.9 schema:alternateName Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France
290 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
291 Pharmacology-Toxicology Laboratory, Hospices Civils de Lyon, South Biology Center, Lyon, France
292 rdf:type schema:Organization
293 grid-institutes:grid.6279.a schema:alternateName Jean Monnet University, Saint-Etienne, France
294 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
295 Jean Monnet University, Saint-Etienne, France
296 Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France
297 rdf:type schema:Organization
298 grid-institutes:grid.7429.8 schema:alternateName Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France
299 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
300 Public Health Department, Hygée Centre, Lucien Neuwirth Cancer Institut, Inserm, CIC1408, 108 bis avenue A. Raimond, 42 270, Saint Priest en Jarez, France
301 rdf:type schema:Organization
302 grid-institutes:grid.7849.2 schema:alternateName EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
303 schema:name EMR3738, Therapeutic Targeting in Oncology, Claude Bernard University, Lyon, France
304 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...